COMPLETE LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently Amended) An isolated monoclonal antibody that is raised against and specifically binds one or more the amidated peptide selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
 - 2. 8. (Canceled)
- 9. (Currently Amended) The antibody of Claim 1, wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), and Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
 - 10. 27. (Canceled)
- 28. (Previously Presented) A diagnostic reagent or kit comprising the antibody of Claim 1.
 - 29. (Canceled)
- 30. (Previously Presented) A hybridoma that produces the antibody according to Claim 1.
 - 31. (Canceled)
 - 32. (Previously Presented) An isolated antibody that specifically binds and is cross-reactive with peptide Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1) and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2), or with peptides Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4) and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).

Express Mail No. EQ 067283343 US

Serial No.: 10/053,669

Attorney Docket No. N1427-005 (800812-0004)

33. (Previously Presented) The isolated antibody of Claim 32, wherein said antibody is a monoclonal antibody.

34. (Currently Amended) A hybridoma that produces the antibody according to Claim 32.